Treatable Traits-Based Pharmacologic Treatment of Sleep Apnea

IF 4.9 Q2 CLINICAL NEUROLOGY Sleep Medicine Clinics Pub Date : 2024-12-10 DOI:10.1016/j.jsmc.2024.10.002

Daniil Lisik MD , Ding Zou MD, PhD

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

基于可治疗特质的睡眠呼吸暂停药物治疗。

阻塞性睡眠呼吸暂停（OSA）是一种异质性疾病，具有多种内源性特征和临床表型。最近一项评估胰高血糖素样肽-1受体激动剂的随机对照试验显示出令人鼓舞的结果，可能使其成为OSA的第一个标签药物治疗。II/III期临床试验正在研究去甲肾上腺素能和抗uscarinic药物以及碳酸酐酶抑制剂的组合。未来OSA的药物治疗，无论是单一治疗还是与其他治疗方式联合，都将是个性化的，并基于可治疗的特征来解决潜在的机制、合并症和患者报告的结果测量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Sleep Medicine Clinics CLINICAL NEUROLOGY-

CiteScore

6.00

自引率

3.60%

发文量

期刊介绍： Sleep Medicine Clinics provides a forum for invited, topical reviews in this rapidly growing field. Each issue, guest edited by a leader in the field of Sleep Medicine, provides expert, state-of-the-art reviews on a single topic, making ample use of figures, diagrams, and tables. Topics such as Obstructive Sleep Apnea, Insomnia, and Parasomnias are presented clearly and comprehensively in the Sleep Medicine Clinics?perfect for any clinician who works with patients suffering from sleep disorders.

期刊最新文献

Contents Hospital Sleep Medicine and Non-Invasive Ventilation: Emerging Clinical Paradigm Copyright Forthcoming Issues Contributors